PLEASE JOIN US FOR A FRIDAY LUNCHEON SYMPOSIUM

Exploring the Controversial Themes of IBD

FRIDAY, DECEMBER 5, 2008
The Westin Diplomat • Great Hall 3 • Hollywood, Florida

AGENDA

12:20 PM – 12:30 PM  Registration and Luncheon Seating
12:30 PM – 1:45 PM  Luncheon Symposium

PROGRAM CHAIR

Stephen B. Hanauer, MD
University of Chicago Pritzker School of Medicine
Chicago, Illinois

PROGRAM FACULTY

Sunanda V. Kane, MD, MSPH
Mayo Clinic
Rochester, Minnesota

Asher A. Kornbluth, MD
Mount Sinai School of Medicine
New York, New York

Edward V. Loftus, Jr., MD
Mayo Clinic
Rochester, Minnesota

A satellite symposium held in conjunction with the 2008 Advances in Inflammatory Bowel Diseases Crohn's & Colitis Foundation’s Clinical & Research Conference

There is no need to preregister for this meeting. Seating is limited and will be available on a first-come, first-served basis; to ensure seating, we recommend that you arrive at the luncheon symposium early.

Co-sponsored by

This activity is supported by an independent educational grant from Procter & Gamble Pharmaceuticals, Inc.
PROGRAM OVERVIEW
Using a fast-paced and dynamic format, this program highlights current information of high relevance to clinicians in their daily care of patients with inflammatory bowel disease (IBD). Drawing on research and clinical experience from their own practice settings, the faculty members address a number of important themes in IBD. These themes, presented in the spirit of various Florida theme parks, include the minimal standards of surveillance in ulcerative colitis (UC), the role of 5-aminosalicylic acid (5-ASA) agents in the treatment/management of Crohn’s disease, the use of 5-ASA agents in maintaining remission after corticosteroid therapy, safety issues related to the continuation of various IBD therapies during pregnancy, and the use of “top-down” therapeutic strategies in IBD.

TARGET AUDIENCE
This activity has been designed to meet the educational needs of gastroenterologists and other health care professionals involved in the care of patients with IBD.

LEARNING OBJECTIVES
At the conclusion of this activity, participants should be able to:
• Compare the utility of standard colonoscopy versus that of emerging surveillance techniques in patients with UC
• Summarize safety issues related to the continuation of various IBD therapies during pregnancy
• Discuss the role of 5-ASA agents in the management of Crohn’s disease
• Describe the role of 5-ASA agents in maintaining remission in patients with Crohn’s disease or UC who have received induction therapy with corticosteroids
• Explain the definition of a “top-down” therapeutic strategy in both Crohn’s disease and UC and discuss what research still needs to be undertaken to support these strategies

ACCREDITATION STATEMENT
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION
The University of Chicago Pritzker School of Medicine designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

DISCLOSURE
The University of Chicago Pritzker School of Medicine and Curatio CME Institute adhere to the ACCME Essential Areas, Standards for Commercial Support, and Policies regarding industry support of continuing medical education. Disclosure of the commercial relationships of everyone in a position to control the content of this educational activity will be made at the activity. Speakers are also required to openly disclose discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.